WALTHAM, Mass., June 11 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a therapy that induces closure and healing offistulas in a greater percentage of patients thanCentocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, wouldearn a 30 percent patient share in the treatment of Crohn's disease, accordingto surveyed gastroenterologists.
The new report entitled Crohn's Disease: Physicians Seek Drugs That TreatFistulizing Disease More Effectively than Infliximab finds that surveyedgastroenterologists indicated that they would prescribeCentocor/Janssen-Cilag's ustekinumab to 30 percent of their patients withCrohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percentpatient share of the U.S. Crohn's disease market in 2012.
The report also finds that UCB's Cimzia will earn Decision Resources'proprietary clinical gold standard ("clinical gold standard") status for thetreatment of Crohn's disease by 2011 as interviewed gastroenterologistsindicate that Cimzia's efficacy and delivery profiles are superior to those ofthe current clinical gold standard, Abbott/Eisai's Humira. Although surveyedgastroenterologists indicated that Cimzia has advantages in efficacy anddelivery, the therapy may be associated with more minor side effects whencompared to Humira.
"Interviewed gastroenterologists report that Cimzia's pegylatedformulation may prolong the drug's effect, resulting in a slightly moreeffective maintenance therapy with a superior maintenance dosing schedule incomparison to Humira," said Kathryn Benton, analyst at Decision Resources. "Asa result, we forecast Cimzia to replace Humira as the clinical gold standardbecause of its incremental advantage in delivery and maintenance of clinicalremission."
About the Report
Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease MoreEffectively than Infliximab is a DecisionBase 2008 report from DecisionResources. DecisionBase 2008 combines market forecasts with clinical andcommercial end points to assess market share projections in 35 indications.These outputs are driven by quantitative and qualitative primary research.DecisionBase 2008 provides detailed market share, patient share, andprice-per-day projections for emerging drugs in development. The market shareprojections are based on prescriber surveys that compare physicians'expectations of a potential target product profile with an emerging productprofile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
SOURCE Decision Resources Inc.